You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Citation Tools

Article menu

Download PDFPDF

Research Article
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Curti B, Daniels GA, McDermott DF, et al
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry
Journal for ImmunoTherapy of Cancer 2017;5:102. doi: 10.1186/s40425-017-0307-5